Digoxin is the most widely used cardiac glycoside globally, inhibiting Na/K-ATPase to increase cardiac contractility and slow AV-nodal conduction, used for heart failure and rate control in atrial fibrillation. Simson Pharma's Digoxin reference standard and impurities support the high-volume compendial and stability-indicating testing this narrow-therapeutic-index cardiac drug demands.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Digoxin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.